No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

NCT02260388Phase 4Completed402 enrolled

Mexiletine for the Treatment of Muscle Cramps in ALS

NCT01811355Phase 4Completed23 enrolled

View all 2 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Oral mexiletine for ventricular tachyarrhythmias treatment in implantable cardioverter-defibrillator patients: a systematic review of the literature.

Ali Hussam, Cristiano Ernesto, Lupo Pierpaolo et al. · Minerva Cardiol Angiol · 2023

PMID: 36305779Meta-Analysis

Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review.

van der Ree Martijn H, van Dussen Laura, Rosenberg Noa et al. · Europace · 2022

PMID: 36036670Meta-AnalysisFull text (PMC)

Mexiletine for recurrent ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter defibrillator: an EHRA systematic review.

Farkowski Michal Miroslaw, Karlinski Michal, Pytkowski Mariusz et al. · Europace · 2022

PMID: 35851797Meta-Analysis

Efficacy and safety of mexiletine in amyotrophic lateral sclerosis: a systematic review of randomized controlled trials.

Adiao Karen Joy, Espiritu Adrian, Bagnas Marjorie Anne · Neurodegener Dis Manag · 2020

PMID: 32867586Meta-Analysis

Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial.

Vivekanandam Vinojini, Skorupinska Iwona, Jayaseelan Dipa L et al. · Lancet Neurol · 2024

PMID: 39304240RCT

Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.

Ruijs Titia Q, Koopmans Ingrid W, de Kam Marieke L et al. · Clin Pharmacol Ther · 2022

PMID: 35762293RCTFull text (PMC)

Mexiletine in spinal and bulbar muscular atrophy: a randomized controlled trial.

Yamada Shinichiro, Hashizume Atsushi, Hijikata Yasuhiro et al. · Ann Clin Transl Neurol · 2022

PMID: 36208052RCTFull text (PMC)

Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double-blind placebo-controlled cross-over study.

Ruijs Titia Q, Koopmans Ingrid W, de Kam Marieke L et al. · Clin Transl Sci · 2022

PMID: 36281627RCTFull text (PMC)

Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.

Heatwole Chad, Luebbe Elizabeth, Rosero Spencer et al. · Neurology · 2021

PMID: 33046619RCTFull text (PMC)

Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.

Stunnenberg Bas C, Woertman Willem, Raaphorst Joost et al. · BMC Neurol · 2015

PMID: 25880166RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Mexiletine (substance)
SNOMED CT: 372909002
UMLS CUI: C0025887
RxNorm CUI: 6926

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.